#1 Clinical Trials Search in Europe

Mexiletine

This article examines the use of mexiletine, a sodium channel blocker, in clinical trials for various neuromuscular disorders. Mexiletine has shown promise in treating conditions like myotonic dystrophy, non-dystrophic myotonias, and amyotrophic lateral sclerosis (ALS). The trials aim to assess the drug’s safety, efficacy, and long-term effects in different patient populations, including adults and children.

Table of Contents

What is Mexiletine?

Mexiletine is a medication that belongs to a class of drugs called antiarrhythmics. It is also known by the brand names Namuscla and Mexitil[1]. Mexiletine was originally developed to treat irregular heart rhythms, but researchers have found that it can also help with certain muscle disorders[2].

What Conditions Does Mexiletine Treat?

Mexiletine is used to treat several conditions affecting muscles and heart rhythm:

  • Non-dystrophic myotonias (NDM): These are rare genetic disorders that cause muscle stiffness and difficulty relaxing muscles after use. Two types of NDM treated with mexiletine are:
    • Myotonia congenita
    • Paramyotonia congenita[3]
  • Myotonic dystrophy: A genetic disorder causing muscle weakness and difficulty relaxing muscles[2]
  • Cardiac arrhythmias: Irregular heart rhythms[4]

Researchers are also studying mexiletine for other conditions, such as:

  • Amyotrophic lateral sclerosis (ALS): A progressive nervous system disease affecting nerve cells in the brain and spinal cord[4]
  • Irritable bowel syndrome with constipation (IBS-C): A disorder affecting the large intestine[5]
  • Focal dystonia: A neurological disorder causing involuntary muscle contractions[6]

How Does Mexiletine Work?

Mexiletine works by affecting the way sodium moves in and out of muscle and nerve cells. This action helps to stabilize cell membranes and reduce abnormal electrical activity. In muscle disorders, this can help muscles relax more easily after contracting. In heart rhythm disorders, it can help regulate the heartbeat[1].

How is Mexiletine Taken?

Mexiletine is usually taken by mouth in the form of capsules. The dosage and frequency can vary depending on the condition being treated and the patient’s response. In clinical trials, some common dosing regimens include:

  • 200 mg three times daily[1]
  • 150 mg three times daily[2]
  • Gradual increase from 200 mg once daily to 200 mg three times daily over the course of a week[3]

It’s important to follow your doctor’s instructions carefully when taking mexiletine.

How Effective is Mexiletine?

Clinical trials have shown that mexiletine can be effective in treating muscle stiffness (myotonia) in patients with non-dystrophic myotonias and myotonic dystrophy. Some of the improvements observed include:

  • Reduced muscle stiffness[2]
  • Faster muscle relaxation after contraction[3]
  • Improved ability to perform daily activities[2]
  • Better quality of life[2]

However, the effectiveness can vary from person to person, and not all patients may experience the same level of improvement.

What are the Potential Side Effects?

Like all medications, mexiletine can cause side effects. Some potential side effects observed in clinical trials include:

  • Gastrointestinal issues (nausea, indigestion)[2]
  • Dizziness[4]
  • Headache[4]
  • Changes in heart rhythm (monitored by ECG)[2]

It’s important to discuss potential side effects with your doctor and report any unusual symptoms while taking mexiletine.

Ongoing Research on Mexiletine

Researchers continue to study mexiletine to better understand its effects and potential uses. Some areas of ongoing research include:

  • Long-term safety and effectiveness in children and adolescents with myotonic disorders[7]
  • Use in treating muscle cramps and twitches in ALS patients[4]
  • Effects on colon function in patients with certain genetic mutations[5]
  • Comparison of different doses to find the most effective and safe treatment regimens[8]

These ongoing studies may provide more information about mexiletine’s benefits and risks in the future.

Aspect Details
Drug Name Mexiletine
Drug Class Sodium channel blocker
Conditions Studied Myotonic dystrophy, Non-dystrophic myotonias, Amyotrophic lateral sclerosis (ALS)
Age Groups Adults, Adolescents (12-17 years), Children (6-11 years)
Primary Outcomes Muscle stiffness, Myotonia severity, Safety and tolerability
Secondary Outcomes Quality of life, Muscle strength, Pain, Fatigue, Electromyography measures
Safety Monitoring Adverse events, ECG changes, Blood tests
Trial Designs Randomized controlled trials, Open-label studies, N-of-1 trials
Dosing Varies by trial; typically 200-600 mg/day, adjusted for age and weight
Duration Range from 6 weeks to 24 months, depending on the study

FAQ

  • What is mexiletine and how does it work? Mexiletine is a sodium channel blocker originally used to treat heart arrhythmias. In neuromuscular disorders, it works by reducing muscle stiffness and myotonia (delayed muscle relaxation) by blocking sodium channels in muscle cells.
  • Which conditions are being studied with mexiletine in clinical trials? Clinical trials are exploring mexiletine's potential in treating myotonic dystrophy, non-dystrophic myotonias, amyotrophic lateral sclerosis (ALS), and other rare neuromuscular disorders affecting both adults and children.
  • What are the main outcomes being measured in these trials? The trials are measuring various outcomes, including changes in muscle stiffness, pain, weakness, quality of life, muscle relaxation times, and safety parameters like adverse events and ECG changes.
  • Are there any trials specifically for children with neuromuscular disorders? Yes, there are trials specifically designed for children and adolescents with myotonic disorders, aiming to assess the safety, efficacy, and appropriate dosing of mexiletine in pediatric populations.
  • What are the potential side effects of mexiletine? Common side effects may include gastrointestinal issues, dizziness, and headache. The trials are closely monitoring for any cardiac effects, as mexiletine can affect heart rhythm in some patients.

Ongoing Clinical Trials on Mexiletine

  • Study Comparing the Safety and Effectiveness of Mexiletine PR and Mexiletine IR for Adults with Non-Dystrophic Myotonias

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy

  • Study on Long-term Safety and Efficacy of Mexiletine for Children with Myotonic Disorders

    Recruiting

    1 1 1 1
    Investigated drugs:
    France

Glossary

  • Myotonic Dystrophy: A genetic disorder characterized by progressive muscle weakness, delayed muscle relaxation (myotonia), and involvement of other organs.
  • Non-dystrophic Myotonias: A group of rare genetic disorders causing muscle stiffness and delayed relaxation without the weakness seen in myotonic dystrophy.
  • Amyotrophic Lateral Sclerosis (ALS): A progressive neurological disease that causes the death of neurons controlling voluntary muscles, leading to muscle weakness and atrophy.
  • Sodium Channel Blocker: A type of medication that works by blocking sodium channels in cells, which can help reduce muscle stiffness and abnormal electrical activity.
  • Myotonia: A symptom characterized by delayed relaxation of muscles after voluntary contraction, often seen in certain neuromuscular disorders.
  • Electrocardiogram (ECG): A test that records the electrical activity of the heart, used to monitor for potential cardiac side effects of mexiletine.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.
  • Visual Analog Scale (VAS): A measurement tool used to assess subjective characteristics or attitudes that cannot be directly measured, often used for pain or symptom severity.
  • Quality of Life (QoL): A measure of an individual's overall well-being, including physical, mental, and social aspects, often assessed in clinical trials to determine treatment impact.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. https://clinicaltrials.gov/study/NCT02045667
  2. https://clinicaltrials.gov/study/NCT01406873
  3. https://clinicaltrials.gov/study/NCT02336477
  4. https://clinicaltrials.gov/study/NCT02781454
  5. https://clinicaltrials.gov/study/NCT01717404
  6. https://clinicaltrials.gov/study/NCT00001784
  7. https://clinicaltrials.gov/study/NCT04624750
  8. https://clinicaltrials.gov/study/NCT01849770